Call Us @ 0172 - 4680800 | info@indswift.com | NSE - BSE
Plazomicin noninferior to meropenem for complicated UTI
 
Plazomicin is noninferior to meropenem for patients with complicated urinary tract infections (UTIs), according to a study and a research letter published in the Feb. 21 issue of the New England Journal of Medicine.

Florian M.E. Wagenlehner, M.D., from Justus Liebig University in Giessen, Germany, and colleagues randomly assigned 609 patients with complicated UTIs, including acute pyelonephritis, to receive intravenous plazomicin or meropenem for a total of seven to 10 days of treatment. The researchers found that with respect to the primary efficacy end point (composite cure, including clinical cure and microbial eradication), plazomicin was noninferior to meropenem. Composite cure was observed in 88.0 and 91.4 percent of patients in the plazomicin and meropenem groups, respectively, on day 5. At the test-of-cure visit (15 to 19 days after therapy initiation), 81.7 and 70.1 percent of patients, respectively, had composite cure.

In a related research letter, James A. McKinnell, M.D., from Los Angeles Biomedical Research Institute, and colleagues randomly assigned patients with bloodstream infection or hospital-acquired or ventilator-associated bacterial pneumonia caused by carbapenem-resistant Enterobacteriaceae infections to plazomicin (18 patients) or colistin (21 patients) combined with adjunctive meropenem or tigecycline. Due to slow enrollment, the trial was stopped early. The researchers found that the primary end-point event (death from any cause at 28 days or clinically significant disease-related complications) occurred in 24 and 50 percent of patients receiving plazomicin and colistin, respectively.
"Establishing a successful environment of antibacterial drug development will require that further scientific, logistic, andeconomic issues be addressed in order to have ongoing development to meet patient needs," write the authors of an accompanying editorial.

(MEDICALEXPRESS.COM)
 
Other Related News:
2019 FDA Approved Drugs
FDA announces another carcinogenic impurity in ARB blood pressure drugs
Researchers identify common genetic signature among three rare skin diseases
Health ministry to amend Section 71 of D&C Rules to make Pharm D professionals eligible to supervise drug manufacturing
3rd International Diabetes Summit to be held in Pune from March 8-10, 2019
Health ministry to roll out common IT platform for management of sales and manufacturing licenses of drugs
Cosmetics licences may come with product composition details to enhance safety; new clause proposed in Cosmetics Rules 2018
T-cell specificity found to play a role in attacks on myelin versus β-synuclein in MS
Plazomicin noninferior to meropenem for complicated UTI
New molecules reverse memory loss linked to depression, aging